Interaction of Apelin and Angiotensin in the Human Forearm Circulation

Not Applicable

Completed

• Conditions: Heart Disease; Vasodilation
• Interventions: Drug: Angiotensin II; Drug: Noradrenaline infusion

• Registration Number: NCT00901745
• Lead Sponsor: University of Edinburgh

Brief Summary

The apelin-APJ system is a relatively new discovery. It has generated interest in part due to it's apparent ability to counteract the renin-angiotensin system, which is frequently overactive in many cardiovascular disease.

Apelin has the ability to cause blood vessels to relax, increasing their diameter and hence blood flow down the blood vessel. The researchers wish to investigate the hypothesis that an infusion of apelin will reduce the effects of angiotensin II, which is know to reduce the diameter of blood vessels.

Detailed Description

Not available

Study Timeline

• Status Verified: 2009-05
• Study Start: 2009-05
• Study First Submitted: 2009-05-13
• Study First Submitted QC: 2009-05-13
• Study First Posted: 2009-05-14
• Primary Completion: 2010-04
• Study Completion: 2010-04
• Last Update Submitted: 2010-08-09
• Last Update Posted: 2010-08-10

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 12

Inclusion Criteria

• > 18 years old
• Healthy volunteers

Exclusion Criteria

• Lack of informed consent

• Age < 18 years,

• Current involvement in other research studies,

• Systolic blood pressure >190 mmHg or <100 mmHg

• Malignant arrhythmias

• Renal or hepatic failure

• Haemodynamically significant aortic stenosis

• Severe or significant co morbidity

• Women of childbearing potential.

• Any regular medication

  • Previous history of any cardiovascular disease

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Infusion of apelin	Noradrenaline infusion	Using forearm venous occlusion plethysmography apelin will be infused to cause reduction in forearm blood flow. Infusion of angiotensin II and noradrenaline will given and vasoconstriction will be assessed. Blood samples for the infused arm and contra-lateral arm will be taken at regular time points to assess local and systemic changes in relevant hormones.
Sodium nitroprusside infusion	Noradrenaline infusion	Using forearm venous occlusion plethysmography sodium nitroprusside will be infused to cause reduction in forearm blood flow. Infusion of angiotensin II and noradrenaline will given and vasoconstriction will be assessed. Blood samples for the infused arm and contra-lateral arm will be taken at regular time points to assess local and systemic changes in relevant hormones.
Infusion of apelin	Angiotensin II	Using forearm venous occlusion plethysmography apelin will be infused to cause reduction in forearm blood flow. Infusion of angiotensin II and noradrenaline will given and vasoconstriction will be assessed. Blood samples for the infused arm and contra-lateral arm will be taken at regular time points to assess local and systemic changes in relevant hormones.
Sodium nitroprusside infusion	Angiotensin II	Using forearm venous occlusion plethysmography sodium nitroprusside will be infused to cause reduction in forearm blood flow. Infusion of angiotensin II and noradrenaline will given and vasoconstriction will be assessed. Blood samples for the infused arm and contra-lateral arm will be taken at regular time points to assess local and systemic changes in relevant hormones.

Primary Outcome Measures

Name	Time	Method
Change in angiotensin II mediated vasoconstriction	12 months

Secondary Outcome Measures

Name	Time	Method
Changes in relevant neurohumoral hormones in response to apelin infusion	12 months

Trial Locations

Locations (1)

Clincial Research Facility, Royal Infirmary of Edinburgh, 51 Little France Cresc; 🇬🇧 Edinburgh, United Kingdom